Citations

Clear

1053 citation(s) found for "Andre, F".

Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
Koach, Jessica , Holien, Jessica K. , Massudi, Hassina, Carter, Daniel R. , Ciampa, Olivia C. , Herath, Mika, Lim, Taylor, Seneviratne, Janith A. , Milazzo, Giorgio , Murray, Jayne , McCarroll, Joshua A. , Liu, Bing , Mayoh, Chelsea , Keenan, Bryce, Stevenson, Brendan W., Gorman, Michael A. , Bell, Jessica L. , Hüttelmaier, Stefan , Oberthuer, André , Fischer, Matthias , Gifford, Andrew J. , Liu, Tao , Zhu, Shizhen , Gustafson, W. Clay , Haber, Michelle , Fletcher, Jamie I. , Perini, Giovanni , Parker, Michael W. , Cheung, Belamy B. , Marshall, Glenn M. , Zhang, Xiaoling , Haber, Michelle , Norris, Murray D , Fletcher, Jamie I , Parker, Michael W , Doughty, Larissa , Zhang, Xiaoling

Mayo Clinic

Cancer Research | September 9, 2019 | Volume: 79 | Issue: 21 | Pages: 5652-5667

10.1158/0008-5472.can-19-1112 | PMID 31501192 Get It

Abstract MYCN is a major driver for the childhood cancer, neuroblastoma, however, there are no inhibitors of this target. Enhanced MYCN protein stability is a key component of MYCN oncogenesis and is maintained by multiple feedforward expression loops involving MYCN transactivation target genes. Here, we reveal the oncogenic role of a novel MYCN target and binding protein, proliferation-associated 2AG4 (PA2G4). Chromatin immunoprecipitation studies demonstrated that MYCN occupies the PA2G4 gene promoter, stimulating transcription. Direct binding of PA2G4 to MYCN protein blocked proteolysis of MYCN and enhanced colony formation in a MYCN-dependent manner. Using molecular modeling, surface plasmon resonance, and mutagenesis studies, we mapped the MYCN–PA2G4 interaction site to a 14 amino acid MYCN sequence and a surface crevice of PA2G4. Competitive chemical inhibition of the MYCN–PA2G4 protein–protein interface had potent inhibitory effects on neuroblastoma tumorigenesis in vivo. Treated tumors showed reduced levels of both MYCN and PA2G4. Our findings demonstrate a critical role for PA2G4 as a cofactor in MYCN-driven neuroblastoma and highlight competitive inhibition of the PA2G4-MYCN protein binding as a novel therapeutic strategy in the disease. Significance: Competitive chemical inhibition of the PA2G4–MYCN protein interface provides a basis for drug design of small molecules targeting MYC and MYCN-binding partners in malignancies driven by MYC family oncoproteins.
Path Toward Proactive Therapy for Patent Ductus Arteriosus
Yamada, Satsuki , Terzic, André

Mayo Clinic

Clinical Pharmacology & Therapeutics | August 21, 2019 | Volume: 106 | Issue: 6 | Pages: 1187-1190

10.1002/cpt.1583 | PMID 31433488 Get It

Transcriptomic Analysis of Cellular Pathways in Healing Flexor Tendons of Plasminogen Activator Inhibitor 1 (PAI‐1/Serpine1) Null Mice
Freeberg, M.A.T. , Easa, Anas, Lillis, Jacquelyn, Benoit, Danielle S. W. , Wijnen, André J. van , Awad, Hani A. , van Wijnen, Andre J , Awad, Hani A

Mayo Clinic

Journal of Orthopaedic Research | August 19, 2019 | Volume: 38 | Issue: 1 | Pages: 43-58

10.1002/jor.24448 | PMID 31424116 Get It

ABSTRACTInjuries to flexor tendons can be complicated by fibrotic adhesions, which severely impair the function of the hand. Plasminogen activator inhibitor 1 (PAI‐1/SERPINE1), a master suppressor of fibrinolysis and protease activity, is associated with adhesions. Here, we used next‐generation RNA sequencing (RNA‐Seq) to assess genome‐wide differences in messenger RNA expression due to PAI‐1 deficiency after zone II flexor tendon injury. We used the ingenuity pathway analysis to characterize molecular pathways and biological drivers associated with differentially expressed genes (DEG). Analysis of hundreds of overlapping and DEG in PAI‐1 knockout (KO) and wild‐type mice (C57Bl/6J) during tendon healing revealed common and distinct biological processes. Pathway analysis identified cell proliferation, survival, and senescence, as well as chronic inflammation as potential drivers of fibrotic healing and adhesions in injured tendons. Importantly, we identified the activation of PTEN signaling and the inhibition of FOXO1‐associated biological processes as unique transcriptional signatures of the healing tendon in the PAI‐1/Serpine1 KO mice. Further, transcriptomic differences due to the genetic deletion of PAI‐1 were mechanistically linked to PI3K/Akt/mTOR, PKC, and MAPK signaling cascades. These transcriptional observations provide novel insights into the biological roles of PAI‐1 in tendon healing and could identify therapeutic targets to achieve scar‐free regenerative healing of tendons. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 38:43–58, 2020
Inhibition of COX‐2 Pathway as a Potential Prophylaxis Against Arthrofibrogenesis in a Rabbit Model of Joint Contracture
Salib, Christopher G. , Reina, Nicolas , Trousdale, William H. , Limberg, Afton K. , Tibbo, Megan E., Jay, Anthony G. , Robin, Joseph X. , Turner, Travis W., Jones, Carter R., Paradise, Christopher R. , Carter, Jodi M. , Berry, Daniel J., Wijnen, André J. van , Berry, Daniel J. , Lewallen, Eric A. , Sanchez-Sotelo, Joaquin, Abdel, Matthew P , van Wijnen, Andre J , van Wijnen, Andre J , Berry, Daniel J , Bolon, Brad , Berry, Daniel J., Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Abdel, Matthew P. , Carter, Jodi

Mayo Clinic

Journal of Orthopaedic Research | August 14, 2019 | Volume: 37 | Issue: 12 | Pages: 2609-2620

10.1002/jor.24441 | PMID 31410880 Get It

ABSTRACTArthrofibrosis is a common complication following total knee arthroplasty caused by pathologic fibroblast activation and excessive collagen deposition around a synovial joint leading to debilitating loss of motion. Treatment options are limited because the pathologic mechanisms remain to be characterized. Dysregulation of the inflammatory cascade may lead to communication between myofibroblasts and immune cells triggering tissue metaplasia, and excessive collagen deposition described clinically as arthrofibrosis. We explored the novel use of celecoxib (selective cyclooxygenase‐2 [COX‐2] inhibitor) to disrupt the downstream effects of the post‐traumatic inflammatory cascade and inhibit scar tissue formation in a validated rabbit model of arthrofibrosis combined with new parameters for quantifying the stiffness of the posterior capsule. Biomechanical and molecular analyses, of contracted rabbit knee posterior capsule tissue after COX‐2 inhibition revealed increased maximal passive extension and down‐regulation of collagen messenger RNA compared with controls. Histopathologic examination suggested a trend of decreased quantities of dense fibrous connective tissue with COX‐2 inhibition. These data may suggest that inhibiting the inflammatory cascade could potentially reduce pathologic myofibroblast activation, thereby reducing scar tissue formation and increasing the range of motion in arthrofibrotic joints. Implementing a multi‐modal pharmacologic approach may simultaneously target numerous cellular components contributing to the complex process of arthrofibrogenesis. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:2609–2620, 2019
RADI-11. NRG ONCOLOGY CC001: A PHASE III TRIAL OF HIPPOCAMPAL AVOIDANCE IN ADDITION TO WHOLE-BRAIN RADIOTHERAPY (WBRT) PLUS MEMANTINE TO PRESERVE NEUROCOGNITIVE FUNCTION IN PATIENTS WITH BRAIN METASTASES (BM)
Deshmukh, Snehal, Gondi, Vinai , Brown, Paul D. , Wefel, Jeffery, Bovi, Joseph , Khuntia, Deepak , Grosshans, David R. , Konski, André , Devisetty, Kiran , Shah, Sunjay, Usuki, Kenneth Y., Anderson, Bethany , Kachnic, Lisa A. , Tomé, Wolfgang A. , Wefel, Jeffery, Armstrong, Terri S. , Bruner, Deborah Watkins , Robinson, Clifford G. , Roberge, David , Kundapur, Vijayananda , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology Advances | August 12, 2019 | Volume: 1 | Issue: Supplement_1 | Pages: i23-i24

10.1093/noajnl/vdz014.104 Get It

Abstract BACKGROUND: NRG CC001, a phase III trial of WBRT+memantine (WBRT+M) with or without Hippocampal Avoidance (HA), sought to assess the neuro-protective effects of lowering the radiation dose received by the hippocampus. METHODS: Patients (pts) with brain metastases were stratified by RPA class and prior radiosurgery/surgery and randomized to either WBRT+M or HA-WBRT+M (30Gy/10 fractions). Standardized neurocognitive function (NCF) tests were performed at baseline, 2, 4, 6, and 12 months (mos.). The primary endpoint was NCF failure, defined as decline using the reliable change index on Hopkins Verbal Learning Test-Revised, Trail Making Test, or Controlled Oral Word Association. Cumulative incidence estimated NCF failure (death without NCF failure was competing risk); between-arms differences tested using Gray’s test. Deterioration at each collection time point was tested using a chi-square test. Patient-reported symptoms were assessed using the MD Anderson Symptom Inventory with Brain Tumor module and analyzed using mixed effects models and t-tests. RESULTS: From 7/2016 to 3/2018, 518 patients were randomized. Median follow-up was 7.9 mos. HA-WBRT+M was associated with lower NCF failure risk (adjusted HR=0.74, p=0.02) due to lower risk of deterioration in executive function at 4 mos. (p=0.01); and encoding (p=0.049) and consolidation (p=0.02) at 6 mos. Age≤61 predicted for lower NCF failure risk (HR=0.60, p=0.0002); non-significant test for interaction indicated independent effects of HA and age. Patient-reported fatigue (p=0.036); difficulty speaking (p=0.049); and problems remembering things (p=0.013) at 6 mos. favored the HA-WBRT+M arm. Imputation models accounting for missing data also favored the HA-WBRT+M arm for patient-reported cognition (p=0.011) and symptom interference (p=0.008) at 6 mos. Treatment arms did not significantly differ in toxicity; intracranial progression or overall survival. CONCLUSIONS: While achieving similar intracranial control and survival; Hippocampal Avoidance during WBRT+M for brain metastases better preserves NCF and patient-reported symptoms. Supported by UG1CA189867 (NCORP) and DCP from the NCI.
Ventricular remodeling in ischemic heart failure stratifies responders to stem cell therapy
Yamada, Satsuki , Arrell, D. Kent , Rosenow, Christian S. , Behfar, Atta , Behfar, Atta , Bartúnek, Jozef , Terzic, André

Mayo Clinic

Stem Cells Translational Medicine | August 2, 2019 | Volume: 9 | Issue: 1 | Pages: 74-79

10.1002/sctm.19-0149 | PMID 31373782 Get It

Abstract Response to stem cell therapy in heart failure is heterogeneous, warranting a better understanding of outcome predictors. This study assessed left ventricular volume, a surrogate of disease severity, on cell therapy benefit. Small to large infarctions were induced in murine hearts to model moderate, advanced, and end-stage ischemic cardiomyopathy. At 1 month postinfarction, cardiomyopathic cohorts with comparable left ventricular enlargement and dysfunction were randomized 1:1 to those that either received sham treatment or epicardial delivery of cardiopoietic stem cells (CP). Progressive dilation and pump failure consistently developed in sham. In comparison, CP treatment produced significant benefit at 1 month post-therapy, albeit with an efficacy impacted by cardiomyopathic stage. Advanced ischemic cardiomyopathy was the most responsive to CP-mediated salvage, exhibiting both structural and functional restitution, with proteome deconvolution substantiating that cell therapy reversed infarction-induced remodeling of functional pathways. Moderate cardiomyopathy was less responsive to CP therapy, improving contractility but without reversing preexistent heart enlargement. In end-stage disease, CP therapy showed the least benefit. This proof-of-concept study thus demonstrates an optimal window, or “Goldilocks principle,” of left ventricular enlargement for maximized stem cell-based cardiac repair. Disease severity grading, prior to cell therapy, should be considered to inform regenerative medicine interventions. Significance statement This article documents that cardiac chamber enlargement postinfarction is a predictor of cardiopoietic stem cell therapy response. Left ventricular size pretherapy could thus serve to guide the selection of ischemic heart failure candidates most suitable to receive a regenerative intervention.
Building the Regenerative Medicine Workforce of the Future: An Educational Imperative
Wyles, Saranya P. , Terzic, André

Mayo Clinic

Regenerative Medicine | July 25, 2019 | Volume: 14 | Issue: 7 | Pages: 613-615

10.2217/rme-2019-0072 | PMID 31342853 Get It

Acquired Idiopathic Stiffness After Total Knee Arthroplasty
Tibbo, Meagan E. , Limberg, Afton K. , Salib, Christopher G. , Ahmed, Ahmed T. , Wijnen, André J. van , Berry, Daniel M. , Abdel, Matthew P. , Berry, Daniel J. , van Wijnen, Andre J , Abdel, Matthew P , Berry, Daniel J , Berry, Daniel J.

Mayo Clinic

Journal of Bone and Joint Surgery | July 18, 2019 | Volume: 101 | Issue: 14 | Pages: 1320-1330

10.2106/jbjs.18.01217 | PMID 31318813 Get It

Background: Stiffness is a common reason for suboptimal clinical outcomes after primary total knee arthroplasty (pTKA). There is a lack of consensus regarding its definition, which is often conflated with its histopathologic subcategory—i.e., arthrofibrosis. There is value in refining the definition of acquired idiopathic stiffness in an effort to select for patients with arthrofibrosis. We conducted a systematic review and meta-analysis to establish a consensus definition of acquired idiopathic stiffness, determine its prevalence after pTKA, and identify potential risk factors for its development. Methods: MEDLINE, Embase, Cochrane Controlled Register of Trials (CENTRAL), and Scopus databases were searched from 2002 to 2017. Studies that included patients with stiffness after pTKA were screened with strict inclusion and exclusion criteria to isolate the subset of patients with acquired idiopathic stiffness unrelated to known extrinsic or surgical causes. Three authors independently assessed study eligibility and risk of bias and collected data. Outcomes of interest were then analyzed according to age, sex, and body mass index (BMI). Results: In the 35 included studies (48,873 pTKAs), the mean patient age was 66 years. In 63% of the studies, stiffness was defined as a range of motion of <90° or a flexion contracture of >5° at 6 to 12 weeks postoperatively. The prevalence of acquired idiopathic stiffness after pTKA was 4%, and this did not differ according to age (4%, I 2 = 95%, among patients <65 years old and 5%, I 2 = 96%, among those ≥65 years old; p = 0.238). The prevalence of acquired idiopathic stiffness was significantly lower in males (1%, I 2 = 85%) than females (3%, I 2 = 95%) (p < 0.0001) as well as in patients with a BMI of <30 kg/m 2 (2%, I 2 = 94%) compared with those with a BMI of ≥30 kg/m 2 (5%, I 2 = 97%) (p = 0.027). Conclusions: Contemporary literature supports the following definition for acquired idiopathic stiffness: a range of motion of <90° persisting for >12 weeks after pTKA in patients in the absence of complicating factors including preexisting stiffness. The mean prevalence of acquired idiopathic stiffness after pTKA was 4%; females and obese patients were at increased risk. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Little Finger Injury - Football
Abadin, Andre A., Cicciaro, John, DeMatas, Kristina, Rosario‐Concepción, Raúl A. , Pujalte, George

Mayo Clinic

Medicine & Science in Sports & Exercise | June 25, 2019 | Volume: 51 | Issue: 6S | Pages: 630-632

10.1249/01.mss.0000562387.69467.08 Get It

Induction of chondrogenic or mesenchymal stem cells from human periodontal ligament cells through inhibition of Twist2 or Klf12
Takai, Hideki , Wijnen, André J. van , van Wijnen, Andre J , Ogata, Yorimasa

Mayo Clinic

Journal of Oral Science | June 17, 2019 | Volume: 61 | Issue: 2 | Pages: 313-320

10.2334/josnusd.18-0224 | PMID 31217381 Get It